Estimation in multi‐arm two‐stage trials with treatment selection and time‐to‐event endpoint

We consider estimation of treatment effects in two‐stage adaptive multi‐arm trials with a common control. The best treatment is selected at interim, and the primary endpoint is modeled via a Cox proportional hazards model. The maximum partial‐likelihood estimator of the log hazard ratio of the selected treatment will overestimate the true treatment effect in this case. Several methods for reducing the selection bias have been proposed for normal endpoints, including an iterative method based on the estimated conditional selection biases and a shrinkage approach based on empirical Bayes theory. We adapt these methods to time‐to‐event data and compare the bias and mean squared error of all methods in an extensive simulation study and apply the proposed methods to reconstructed data from the FOCUS trial. We find that all methods tend to overcorrect the bias, and only the shrinkage methods can reduce the mean squared error. © 2017 The Authors. Statistics in Medicine Published by John Wiley & Sons Ltd.

[1]  L Di Scala,et al.  Time‐to‐event analysis with treatment arm selection at interim , 2011, Statistics in medicine.

[2]  Jack Bowden,et al.  Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials , 2013, Biometrical journal. Biometrische Zeitschrift.

[3]  Jiunn T. Hwang.  EMPIRICAL BAYES ESTIMATION FOR THE MEANS OF THE SELECTED POPULATIONS , 2016 .

[4]  M. Parmar,et al.  Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome , 2013, Trials.

[5]  D. Slepian.  The one-sided barrier problem for Gaussian noise , 1962 .

[6]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[7]  Werner Brannath,et al.  Shrinkage estimation in two‐stage adaptive designs with midtrial treatment selection , 2013, Statistics in medicine.

[8]  Harold B. Sackrowitz,et al.  Two stage conditionally unbiased estimators of the selected mean , 1989 .

[9]  Frank Bretz,et al.  TUTORIAL IN BIOSTATISTICS Adaptive designs for confirmatory clinical trials , 2022 .

[10]  Jack Bowden,et al.  Unbiased estimation in seamless phase II/III trials with unequal treatment effect variances and hypothesis‐driven selection rules , 2016, Statistics in medicine.

[11]  T Friede,et al.  Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis , 2011, Statistics in medicine.

[12]  Nigel Stallard,et al.  Point estimates and confidence regions for sequential trials involving selection , 2005 .

[13]  Jing Shen,et al.  The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[14]  Nigel Stallard,et al.  Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.

[15]  W. Brannath,et al.  Selection and bias—Two hostile brothers , 2009, Statistics in medicine.

[16]  J. Whitehead,et al.  A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .

[17]  Nigel Stallard,et al.  Sequential designs for phase III clinical trials incorporating treatment selection , 2003, Statistics in medicine.

[18]  John Whitehead,et al.  Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference 138, 1629-1638. , 2008 .

[19]  Zhiliang Ying,et al.  Towards a general asymptotic theory for Cox model with staggered entry , 1997 .

[20]  T. Jaki.  Multi-arm clinical trials with treatment selection: what can be gained and at what price? , 2015 .

[21]  Thomas Jaki,et al.  Some recommendations for multi-arm multi-stage trials , 2012, Statistical methods in medical research.

[22]  P. Royston,et al.  How do multi-stage, multi-arm trials compare to the traditional two-arm parallel group design – a reanalysis of 4 trials , 2009, Trials.

[23]  Richard J Stephens,et al.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.

[24]  Patrick Royston,et al.  Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer , 2003, Statistics in medicine.

[25]  Jack Bowden,et al.  Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials , 2008, Biometrical journal. Biometrische Zeitschrift.

[26]  C. Morris.  Parametric Empirical Bayes Inference: Theory and Applications , 1983 .

[27]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[28]  P. J. Verweij,et al.  Penalized likelihood in Cox regression. , 1994, Statistics in medicine.

[29]  D Magirr,et al.  Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments. , 2013, Statistics in medicine.